Izvorni znanstveni članak
Cutaneous T-cell Lymphomas: A Single-center Retrospective Analysis
Till Kaemmerer
; Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany
Anne Guertler
; Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany
Benjamin M. Clanner-Engelshofen
; Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany
Corbinian Fuchs
; Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany
Lars Einar French
; Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany
Markus Reinholz
; Department of Dermatology and Allergy, University Hospital, LMU Munich, Germany
Sažetak
Cutaneous T-cell lymphomas (CTCLs) are rare diseases char-
acterized by infiltration of malignant T-cells into the skin. We evaluated the
prevalence, epidemiology, and therapy of CTCLs, focusing on its most well-
known subtypes, namely mycosis fungoides (MF) and Sézary syndrome (SS).
Patients and methods: We retrospectively analyzed the medical data of pa-
tients with a histologically confirmed diagnosis of CTCL presenting to our
outpatient department during a 5-year period from January 2015 to Decem-
ber 2019.
Results: We evaluated the files of 102 patients, of whom 67% were men and
33% women. The overall mean age was 59.1±14.1 (24-86) years. Ninety-two
patients (90%) were diagnosed with MF and ten patients (10%) with SS. Ac-
cording to ISCL/EORTC, the majority of patients initially classified as stage IA
(34%) and IB (45%). Disease frequency decreased at advanced stages (II: 4%;
III: 7%; IV: 10%). Forty-five patients (44.1%) received only skin-directed ther-
apy (SDT). Twenty patients (19.6%) progressed from SDT to systemic therapy
(ST). Thirty-seven patients (36.3%) received ST combined with SDT (TS) from
the start of treatment. Overall, fifty different therapeutic approaches of TS
were initiated due to lack of response to therapy or disease progression.
Conclusion: Management of CTCLs aims to maintain patient quality of life
while minimizing side-effects. As CTCLs are usually incurable diseases, the
focus of treatment is on symptom control and prevention of disease progres-
sion. Due to the large patient group and the long observation period, our
study allows for a valid evaluation of the frequency and therapy of MF and
SS in a university outpatient clinic in Germany. We favor topical therapies in
early stages with more invasive therapies in advanced stages.
Ključne riječi
CTCL; cutaneous T-cell lymphoma; retrospective; mycosis fun- goides; Sézary syndrome
Hrčak ID:
316452
URI
Datum izdavanja:
15.12.2023.
Posjeta: 0 *